Orphan drugs for the treatment of hereditary angioedema

Bibliography

• Milton JL. On giant urticaria. Edinburgh J Med 1876;22(6):513-26
   Google Scholar
• Osler W. Hereditary angioneurotic oedema. Am J Med Sci 1888;95(2):362-7
   Google Scholar
• Crowder JR, Crowder TR. Five generations of angioneurotic edema. Arch Intern Med 1917;20:840-52
   Google Scholar
• Levy LR, Lepow IH. Assay and properties of serum inhibitor of C'l-esterase. Proc Soc Exp Biol Med 1959;101:608-11
   PubMed Web of Science ®Google Scholar
• Pensky J, Levy LR, Lepow IH. Partial purification of a serum inhibitor of C'1-esterase. J Biol Chem 1961;236:1674-9
   PubMed Web of Science ®Google Scholar
• Landerman NS, Webster ME, Becker EL, Ratcliffe HE. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy 1962;33:330-41
   PubMedGoogle Scholar
• Donaldson VH, Evans RR. A Biochemical abnormality in herediatry angioneurotic edema: absence of serum inhibitor of c' 1-Esterase. Am J Med 1963;35:37-44
   PubMed Web of Science ®Google Scholar
• Rosen FS, Pensky J, Donaldson V, Charache P. Hereditary Angioneurotic Edema: two Genetic Variants. Science 1965;148(3672):957-8
   PubMed Web of Science ®Google Scholar
• Stoppa-Lyonnet D, Tosi M, Laurent J, Altered C1 inhibitor genes in type I hereditary angioedema. N Engl J Med 1987;317(1):1-6
   PubMed Web of Science ®Google Scholar
• Tosi M, Stoppa-Lyonnet D, Carter P, Meo T. Molecular defects of the C1-inhibitor gene in hereditary angioedema. Behring Inst Mitt 1989(84):173-9
   PubMedGoogle Scholar
• Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000;356(9225):213-17
   PubMed Web of Science ®Google Scholar
• Binkley KE, Davis A III. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol 2000;106(3):546-50
   PubMed Web of Science ®Google Scholar
• Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006;343(4):1286-9
   PubMed Web of Science ®Google Scholar
• Cichon S, Martin L, Hennies HC, Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006;79(6):1098-104
   PubMed Web of Science ®Google Scholar
• Bork K, Wulff K, Meinke P, A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol 2011;141(1):31-5
   PubMed Web of Science ®Google Scholar
• Nussberger J, Cugno M, Amstutz C, Plasma bradykinin in angio-oedema. Lancet 1998;351(9117):1693-7
   PubMed Web of Science ®Google Scholar
• Shoemaker LR, Schurman SJ, Donaldson VH, Davis AE III. Hereditary angioneurotic oedema: characterization of plasma kinin and vascular permeability-enhancing activities. Clin Exp Immunol 1994;95(1):22-8
   Google Scholar
• Han ED, MacFarlane RC, Mulligan AN, Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002;109(8):1057-63
   PubMed Web of Science ®Google Scholar
• Cugno M, Zanichelli A, Bellatorre AG, Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency. Allergy 2009;64(2):254-7
   PubMed Web of Science ®Google Scholar
• Kaplan AP. Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. J Allergy Clin Immunol 2010;126(5):918-25
   PubMed Web of Science ®Google Scholar
• Agostoni A, Aygoren-Pursun E, Binkley KE, Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004;114(3 Suppl):S51-131
   PubMed Web of Science ®Google Scholar
• Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006;119(3):267-74
   PubMed Web of Science ®Google Scholar
• Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012;130(3):692-7
   PubMed Web of Science ®Google Scholar
• Farkas H, Harmat G, Kaposi PN, Ultrasonography in the diagnosis and monitoring of ascites in acute abdominal attacks of hereditary angioneurotic oedema. Eur J Gastroenterol Hepatol 2001;13(10):1225-30
   PubMed Web of Science ®Google Scholar
• Bork K, Staubach P, Eckardt AJ, Hardt J. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 2006;101(3):619-27
   PubMed Web of Science ®Google Scholar
• Nzeako UC, Longhurst HJ. Many faces of angioedema: focus on the diagnosis and management of abdominal manifestations of hereditary angioedema. Eur J Gastroenterol Hepatol 2012;24(4):353-61
   PubMed Web of Science ®Google Scholar
• Prematta MJ, Bewtra AK, Levy RJ, Per-attack reporting of prodromal symptoms concurrent with c1-inhibitor treatment of hereditary angioedema attacks. Adv Ther 2012;29(10):913-22
   Google Scholar
• Spaulding WB. Methyltestosterone therapy for hereditary episodic edema. Ann Intern Med 1963;53:739-45
   Google Scholar
• Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976;295(26):1444-8
   PubMed Web of Science ®Google Scholar
• Pappalardo E, Zingale LC, Cicardi M. Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with Danazol. Immunol Lett 2003;86(3):271-6
   PubMed Web of Science ®Google Scholar
• Cicardi M, Bergamaschini L, Cugno M, Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. J Allergy Clin Immunol 1991;87(4):768-73
   PubMed Web of Science ®Google Scholar
• Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008;100(2):153-61
   PubMed Web of Science ®Google Scholar
• Fust G, Farkas H, Csuka D, Long-term efficacy of danazol treatment in hereditary angioedema. Eur J Clin Invest 2011;41(3):256-62
   PubMedGoogle Scholar
• Bork K, Pitton M, Harten P, Koch P. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. Lancet 1999;353(9158):1066-7
   PubMedGoogle Scholar
• Szeplaki G, Varga L, Valentin S, Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. J Allergy Clin Immunol 2005;115(4):864-9
   PubMed Web of Science ®Google Scholar
• Cicardi M, Castelli R, Zingale LC, Agostoni A. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997;99(2):194-6
   PubMed Web of Science ®Google Scholar
• Zurlo JJ, Frank MM. The long-term safety of danazol in women with hereditary angioedema. Fertil Steril 1990;54(1):64-72
   Google Scholar
• Sloane DE, Lee CW, Sheffer AL. Hereditary angioedema: safety of long-term stanozolol therapy. J Allergy Clin Immunol 2007;120(3):654-8
   PubMedGoogle Scholar
• Craig TJ. Appraisal of danazol prophylaxis for hereditary angioedema. Allergy Asthma Proc 2008;29(3):225-31
   PubMed Web of Science ®Google Scholar
• Duck SC, Katayama KP. Danazol may cause female pseudohermaphroditism. Fertil Steril 1981;35(2):230-1
   PubMedGoogle Scholar
• Reschini E, Giustina G, D'Alberton A, Candiani GB. Female pseudohermaphroditism due to maternal androgen administration: 25-year follow-up. Lancet 1985;1(8439):1226
   Google Scholar
• Sathishkumar K, Elkins R, Yallampalli U, Yallampalli C. Elevated androgens levels during pregnancy impair fetal growth due to placental insufficiency and programs for adult hypertension in rats. Biol Reprod 2009;81
   Google Scholar
• Barakat A, Castaldo AJ. Hereditary angioedema: danazol therapy in a 5-year-old child. Am J Dis Child 1993;147(9):931-2
   PubMedGoogle Scholar
• Church JA. Oxandrolone treatment of childhood hereditary angioedema. Ann Allergy Asthma Immunol 2004;92(3):377-8
   Google Scholar
• Farkas H. Pediatric hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Clin Immunol 2010;6(1):18
   PubMedGoogle Scholar
• Farkas H, Csuka D, Zotter Z, Prophylactic therapy in children with hereditary angioedema. J Allergy Clin Immunol 2012; Epub 2012/09/28
   Google Scholar
• Farkas H, Czaller I, Csuka D, The effect of long-term danazol prophylaxis on liver function in hereditary angioedema-a longitudinal study. Eur J Clin Pharmacol 2010;66(4):419-26
   PubMedGoogle Scholar
• Farkas H, Zotter Z, Csuka D, Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor - a long-term survey. Allergy 2012;67(12):1586-93
   PubMed Web of Science ®Google Scholar
• Frank MM. Hereditary angioedema: short-term prophylaxis for surgery. Allergy Asthma Proc 2012;33(4):303-4
   PubMedGoogle Scholar
• Farkas H, Gyeney L, Gidofalvy E, The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures. J Oral Maxillofac Surg 1999;57(4):404-8
   PubMedGoogle Scholar
• Martin L, Degenne D, Toutain A, Hereditary angioedema type III: an additional French pedigree with autosomal dominant transmission. J Allergy Clin Immunol 2001;107(4):747-8
   PubMedGoogle Scholar
• Herrmann G, Schneider L, Krieg T, Efficacy of danazol treatment in a patient with the new variant of hereditary angio-oedema (HAE III). Br J Dermatol 2004;150(1):157-8
   PubMedGoogle Scholar
• Bork K. Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. Immunol Allergy Clin North Am 2006;26(4):709-24
   PubMed Web of Science ®Google Scholar
• Lundh B, Laurell AB, Wetterqvist H, A case of hereditary angioneurotic oedema, successfully treated with epsilon-aminocaproic acid. Studies on C'1 esterase inhibitor, C'1 activation, plasminogen level and histamine metabolism. Clin Exp Immunol 1968;3(7):733-45
   Google Scholar
• Frank MM, Sergent JS, Kane MA, Alling DW. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med 1972;286(15):808-12
   PubMed Web of Science ®Google Scholar
• Kleniewski J, Blankenship DT, Cardin AD, Donaldson V. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J Lab Clin Med 1992;120(1):129-39
   PubMed Web of Science ®Google Scholar
• van Geffen M, Cugno M, Lap P, Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency. Clin Exp Immunol 2012;167(3):472-8
   PubMed Web of Science ®Google Scholar
• Zanichelli A, Vacchini R, Badini M, Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy 2011;66(2):192-6
   PubMed Web of Science ®Google Scholar
• Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 1976;84(5):580-93
   PubMed Web of Science ®Google Scholar
• Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 1972;287(9):452-4
   PubMed Web of Science ®Google Scholar
• Cyklokapron (Pharmacia). Krogh CME. editor. CPS Compendium of pharmaceuticals and specialties. 22nd edition. Canadian Pharmaceutical Association; Ottawa: 1987
   Google Scholar
• Sundstrom A, Seaman H, Kieler H, Alfredsson L. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. BJOG 2009;116(1):91-7
   PubMedGoogle Scholar
• Bork K, Wulff K, Hardt J, Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol 2009;124(1):129-34
   PubMedGoogle Scholar
• Bouillet L, Longhurst H, Boccon-Gibod I, Disease expression in women with hereditary angioedema. Am J Obstet Gynecol 2008;199(5):484 e1-4
   Google Scholar
• Amar L, Lidove O, Kahn JE, Hereditary angio-oedema: effective treatment with the progestogen-only pill in a young woman. Br J Dermatol 2004;151(3):713-14
   Google Scholar
• Wautier JL, Caen JP. [Norgestrienone, a possible therapeutic agent in hereditary angioneurotic edema]. Presse Med 1986;15(40):2023
   Google Scholar
• Pickering RJ, Good RA, Kelly JR, Gewurz H. Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet 1969;1(7590):326-30
   PubMed Web of Science ®Google Scholar
• Tang R, Chen S, Zhang HY. Fresh frozen plasma for the treatment of hereditary angioedema acute attacks. Chin Med Sci J 2012;27(2):92-5
   Google Scholar
• Prematta M, Gibbs JG, Pratt EL, Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 2007;98(4):383-8
   PubMed Web of Science ®Google Scholar
• Agostoni A, Cicardi M. Replacement therapy in hereditary and acquired angioedema. Pharmacol Res 1992;26(Suppl 2):148-9
   Google Scholar
• Inbal A, Epstein O, Blickstein D, Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders. Blood coagul Fibrinolys 1993;4(4):599-604
   Google Scholar
• Galan HL, Reedy MB, Starr J, Knight AB. Fresh frozen plasma prophylaxis for hereditary angioedema during pregnancy. A case report. J Reprod Med 1996;41(7):541-4
   PubMedGoogle Scholar
• McGlinchey PG, Golchin K, McCluskey DR. Life-threatening laryngeal oedema in a pregnant woman with hereditary angioedema. Ulster Med J 2000;69(1):54-7
   Google Scholar
• Pekdemir M, Ersel M, Aksay E, Effective treatment of hereditary angioedema with fresh frozen plasma in an emergency department. J Emerg Med 2007;33(2):137-9
   PubMed Web of Science ®Google Scholar
• Brackertz D, Kueppers F. Hereditary angioneurotic oedema. Lancet 1973;2(7830):680
   PubMed Web of Science ®Google Scholar
• Vogelaar EF, Brummelhuis HG, Krijnen HW. Contributions to the optimal use of human blood. 3. Large-scale preparation of human c1 esterase inhibitor concentrate for clinical use. Vox Sang 1974;26(2):118-27
   PubMed Web of Science ®Google Scholar
• Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996;334(25):1630-4
   PubMed Web of Science ®Google Scholar
• Groner A, Nowak T, Schafer W. Pathogen safety of human C1 esterase inhibitor concentrate. Transfusion 2012;52(10):2104-12
   PubMed Web of Science ®Google Scholar
• Hofstra JJ, Kleine Budde I, van Twuyver E, Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor(R)): multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety. Clin Immunol 2012;142(3):280-90
   PubMedGoogle Scholar
• Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006;117(4):904-8
   PubMed Web of Science ®Google Scholar
• Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001;161(5):714-18
   PubMed Web of Science ®Google Scholar
• Bork K, Meng G, Staubach P, Hardt J. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 2005;45(11):1774-84
   PubMed Web of Science ®Google Scholar
• Bork K, Staubach P, Hardt J. Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema. Allergy 2008;63(6):751-7
   PubMed Web of Science ®Google Scholar
• Farkas H, Jakab L, Temesszentandrasi G, Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol 2007;120(4):941-7
   PubMed Web of Science ®Google Scholar
• Craig TJ, Levy RJ, Wasserman RL, Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009;124(4):801-8
   PubMed Web of Science ®Google Scholar
• Craig TJ, Wasserman RL, Levy RJ, Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J Clin Immunol 2010;30(6):823-9
   PubMed Web of Science ®Google Scholar
• Bork K, Hardt J. Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week. Int Arch Allergy Immunol 2011;154(1):81-8
   PubMedGoogle Scholar
• Farkas H, Csuka D, Zotter Z, Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients. J Allergy Clin Immunol 2012; Epub 2012/10/16
   Google Scholar
• Martinez-Saguer I, Rusicke E, Aygoren-Pursun E, Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol 2010;203(2):131 e1-7
   Google Scholar
• Czaller I, Visy B, Csuka D, The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. Eur J Obstet Gynecol Reprod Biol 2010;152(1):44-9
   PubMed Web of Science ®Google Scholar
• Tourangeau LM, Castaldo AJ, Davis DK, Safety and efficacy of physician-supervised self-managed C1 inhibitor replacement therapy. Int Arch Allergy Immunol 2012;157(4):417-24
   PubMed Web of Science ®Google Scholar
• Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009;19(2):147-51
   PubMed Web of Science ®Google Scholar
• De Serres J, Groner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. [email protected]. Transfus Apher Sci 2003;29(3):247-54
   PubMed Web of Science ®Google Scholar
• Varga L, Fust G, Csuka D, Farkas H. Treatment with C1-inhibitor concentrate does not induce IgM type anti-C1 inhibitor antibodies in patients with hereditary angioedema. Mol Immunol 2011;48(4):572-6
   PubMedGoogle Scholar
• Riedl MA, Hurewitz DS, Levy R, Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial. Ann Allergy Asthma Immunol 2012;108(1):49-53
   PubMed Web of Science ®Google Scholar
• Zuraw BL, Kalfus I. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med 2012;125(9):938 e1-7
   PubMed Web of Science ®Google Scholar
• Zuraw BL, Busse PJ, White M, Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010;363(6):513-22
   PubMed Web of Science ®Google Scholar
• Grant JA, White MV, Li HH, Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks. Allergy Asthma Proc 2012;33(4):348-53
   Google Scholar
• Bock SC, Skriver K, Nielsen E, Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry 1986;25(15):4292-301
   PubMed Web of Science ®Google Scholar
• Choi G, Soeters MR, Farkas H, Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 2007;47(6):1028-32
   PubMed Web of Science ®Google Scholar
• Zuraw B, Cicardi M, Levy RJ, Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010;126(4):821-7.e14
   PubMed Web of Science ®Google Scholar
• Moldovan D, Reshef A, Fabiani J, Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: european open-label extension study. Clin Exp Allergy 2012;42(6):929-35
   PubMed Web of Science ®Google Scholar
• Hock FJ, Wirth K, Albus U, Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 1991;102(3):769-73
   PubMed Web of Science ®Google Scholar
• Marceau F, Regoli D. Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 2004;3(10):845-52
   Google Scholar
• Bork K, Frank J, Grundt B, Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 2007;119(6):1497-503
   PubMed Web of Science ®Google Scholar
• Cicardi M, Banerji A, Bracho F, Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010;363(6):532-41
   PubMed Web of Science ®Google Scholar
• Lumry WR, Li HH, Levy RJ, Randomized placebo-controlled trial of the bradykinin B(2) receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011;107(6):529-37
   PubMed Web of Science ®Google Scholar
• Bouillet L, Boccon-Gibod I, Ponard D, Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. Ann Allergy Asthma Immunol 2009;103(5):448
   PubMed Web of Science ®Google Scholar
• Boccon-Gibod I, Bouillet L. Safety and efficacy of icatibant self-administration for acute hereditary angioedema. Clin Exp Immunol 2012;168(3):303-7
   PubMedGoogle Scholar
• Farkas H, Csuka D, Zotter Z, Home treatment of hereditary angioedema with icatibant administered by health care professionals. J Allergy Clin Immunol 2012;129(3):851-2 e2
   PubMed Web of Science ®Google Scholar
• Senaratne KT, Cottrell AM, Prentice RI. Successful perioperative management of a patient with C1 esterase inhibitor deficiency with a novel bradykinin receptor B2 antagonist. Anaesth Intensive Care 2012;40(3):523-6
   PubMed Web of Science ®Google Scholar
• Schneider L, Lumry W, Vegh A, Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 2007;120(2):416-22
   PubMed Web of Science ®Google Scholar
• Cicardi M, Levy RJ, McNeil DL, Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010;363(6):523-31
   PubMed Web of Science ®Google Scholar
• Levy RJ, Lumry WR, McNeil DL, EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010;104(6):523-9
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Shea EP, Koester J, Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema. Allergy 2012;67(9):1173-80
   Google Scholar
• Stolz LE, Sheffer AL. Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema. Expert Rev Clin Immunol 2012;8(1):25-32
   PubMed Web of Science ®Google Scholar
• MacGinnitie AJ, Campion M, Stolz LE, Pullman WE. Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics. Allergy Asthma Proc 2012;33(2):178-85
   PubMedGoogle Scholar
• Bowen T, Cicardi M, Farkas H, Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. J Allergy Clin Immunol 2004;114(3):629-37
   Google Scholar
• Bowen T, Cicardi M, Bork K, Hereditary angiodema: a current state-of-the-art review, VII: canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol 2008;100(1 Suppl 2):S30-40
   Google Scholar
• Bowen T, Cicardi M, Farkas H, 2010;International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010;6(1):24
   PubMedGoogle Scholar
• Cicardi M, Bork K, Caballero T, Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012;67(2):147-57
   PubMed Web of Science ®Google Scholar
• Gompels MM, Lock RJ, Abinun M, C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005;139(3):379-94
   PubMed Web of Science ®Google Scholar
• Horiuchi T, Ohi H, Ohsawa I, Guideline for Hereditary Angioedema (HAE) 2010 by the Japanese association for Complement Research - Secondary Publication. Allergol Int 2012; Epub 2012/10/25
   Google Scholar
• Giavina-Bianchi P, Franca AT, Grumach AS, Brazilian guidelines for the diagnosis and treatment of hereditary angioedema. Clinics (Sao Paulo) 2011;66(9):1627-36
   Google Scholar
• Caballero T, Baeza ML, Cabanas R, Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J Investig Allergol Clin Immunol 2011;21(5):333-47; quiz follow 47
   PubMed Web of Science ®Google Scholar
• Caballero T, Baeza ML, Cabanas R, Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations. J Investig Allergol Clin Immunol 2011;21(6):422-41; quiz 42-3
   PubMed Web of Science ®Google Scholar
• Bowen T, Hebert J, Ritchie B, Management of hereditary angioedema: a Canadian approach. Transfus Apher Sci 2003;29(3):205-14
   Google Scholar
• Jaiganesh T, Hughan C, Webster A, Bethune C. Hereditary angioedema: a survey of UK emergency departments and recommendations for management. European j Emerg Med 2012;19(4):271-4
   Google Scholar
• Katelaris C, Smith W, Mullins R, Gillis D. Position Paper on Hereditary Angioedema. Australasian Society of Clinical Immunology and Allergy. 2012. Available from: http://www.allergy.org.au/images/stories/pospapers/ASCIA_HAE_Position_Paper_August_2012.pdf
   Google Scholar
• Caballero T, Farkas H, Bouillet L, International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012;129(2):308-20
   PubMed Web of Science ®Google Scholar
• Longhurst HJ, Farkas H, Craig T, HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010;6(1):22
   PubMedGoogle Scholar
• Boyle RJ, Nikpour M, Tang ML. Hereditary angio-oedema in children: a management guideline. Pediatr Allergy Immunol 2005;16(4):288-94
   Google Scholar
• Farkas H, Varga L, Szeplaki G, Management of hereditary angioedema in pediatric patients. Pediatrics 2007;120(3):e713-22
   Google Scholar
• Wahn V, Aberer W, Eberl W, Hereditary angioedema (HAE) in children and adolescents–a consensus on therapeutic strategies. Eur J Pediatr 2012;171(9):1339-48
   Google Scholar
• Bork K. Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor. Allergy Asthma Clin Immunol 2010;6(1):15
   PubMedGoogle Scholar
• Binkley KE. Factor XII mutations, estrogen-dependent inherited angioedema, and related conditions. Allergy Asthma Clin Immunol 2010;6(1):16
   PubMedGoogle Scholar
• Kaplan A. Type III hereditary angioedema: defined, but not understood. Ann Allergy Asthma Immunol 2012;109(3):153-4
   Google Scholar
• Craig T, Riedl M, Dykewicz MS, When is prophylaxis for hereditary angioedema necessary? Ann Allergy Asthma Immunol 2009;102(5):366-72
   PubMed Web of Science ®Google Scholar
• Wilson DA, Bork K, Shea EP, Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol 2010;104(4):314-20
   PubMed Web of Science ®Google Scholar